Riv. Mat. Univ. Parma, Vol. 12, No. 2, 2021

Hajimohammad Mohammadinejad [a], Saeed Jani [a] and Omid RabieiMotlagh [a]

Mathematical analysis for oncolytic virotherapy
Pages: 221-238
Received: 4 August 2020
Accepted in revised form: 14 June 2021
Mathematics Subject Classification: 37N25, 97M99, 34K20.
Keywords: Hopf bifurcation, Stability, Cancer virotherapy.
Authors address:
[a]:University of Birjand, Birjand, 0098, Iran.

Full Text (PDF)

Abstract: In this paper, we introduce a mathematical model for cancer virotherapy. The model simulates the coeffects of tumor cells and CTLs by considering the time delay of the viral lytic cycle. This delay has been recently seen in some clinical observations when the tumor size changes with a time delay after the virus injection. We investigate the stability of equilibrium points of the model and the corresponding biological interpretation. The model simulates some aspects of the phenomenon which have not been recorded by the former models. For example, a Hopf bifurcation occurs in the delayed model showing an oscillation in the size of the tumor. We indicate natural limitations of the therapy process; for example, the oncolytic virus must be modified such that the time of the delay of the lytic cycle is less than the Hopf bifurcation value.

References
[1]
D. Cervantes-García, R. Ortiz-López, N. Mayek-Pérez and A. Rojas-Martínez, Oncolytic virotherapy, Ann. Hepatol. 7 (2008), 34-45. DOI
[2]
D. H. Kirn and F. McCormick, Replicating viruses as selective cancer therapeutics, Mol. Med. Today 2 (1996), 519-527. DOI
[3]
M. S. Roberts, R. M. Lorence, W. S. Groene and M. K. Bamat, Naturally oncolytic viruses, Curr. Opin. Mol. Ther. 8 (2006), 314-321. PubMed
[4]
J. M. Kaplan, Adenovirus-based cancer gene therapy, Curr. Gene Ther. 5 (2005), 595-605. DOI
[5]
E. Kelly and S. J. Russell, History of oncolytic viruses: genesis and genetic engineering, Mol. Ther. 15 (2007), 651-659. DOI
[6]
R. J. Huebner, W. P. Rowe, W. E. Schatten, R. R. Smith and L. B. Thomas, Studies on the use of viruses in the treatment of carcinoma of the cervix, Cancer 9 (1956), 1211-1218. DOI
[7]
C. M. Kunin, Cellular susceptibility to enteroviruses, Bacteriol. Rev. 28 (1964), 382-390. DOI
[8]
A. E. Moore, The destructive effect of the virus of Russian far east encephalitis on the transplantable mouse sarcoma \(180\), Cancer 2 (1949), 525-534. DOI
[9]
L. Pelner, G. A. Fowler and H. C. Nauts, Effects of concurrent infections and their toxins on the course of leukemia, Acta. Med. Scand. Suppl. 338 (1958), 1-47. Pubmed
[10]
A. R. Pond and E. E. Manuelidis, Oncolytic effect of poliomyelitis virus on human epidermoid carcinoma (Hela tumor) heterologously transplanted to Guinea pigs, Am. J. Pathol. 45 (1964), 233-249. Pubmed
[11]
S. Friberg and S. Mattson, On the growth rates of human malignant tumors: implications for medical decision making, J. Surg. Oncol. 65 (1997), 284-297. Pubmed  |  DOI
[12]
A.-M. Maatta, T. Liimatainen, T. Wahlfors, T. Wirth, M. Vaha-Koskela, L. Jansson, P. Valonen, K. Hakkinen, O. Rautsi, R. Pellinen, K. Makinen, J. Hakumaki, A. Hinkkanen and J. Wahlfors, Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models, Int. J. Cancer. 121 (2007), 863-870. DOI
[13]
J.-L. Hsieh, C.-H. Lee, M.-L. Teo, Y.-J. Lin, Y.-S. Huang, C.-L. Wu and A.-L. Shiau, Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma, Cancer Sci. 100 (2009), 537-545. DOI
[14]
H. Fukuhara, Y. Homma and T. Todo, Oncolytic virus therapy for prostate cancer, Int. J. Urol. 17 (2010), 20-30. DOI
[15]
S. F. Bonab and N. Khansari, Virotherapy with Newcastle Disease Virus for Cancer Treatment and its Efficacy in Clinical Trials, MOJ Immunol. 5 (2017), 00176, DOI: 10.15406/moji.2017.05.00176.
[16]
B. Xu, W. Zheng, D. Jin, D. Wang, X. Liu and X. Qin, Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene, Cancer 118 (2012), 5217-5226. DOI
[17]
J. P. Tian, The replicability of oncolytic virus: defining conditions in tumor virotherapy, Math. Biosci. Eng. 8 (2011), 841-860. DOI  |  Pubmed
[18]
N. L. Komarova and D. Wodarz, ODE models for oncolytic virus dynamics, J. Theor. Biol. 263 (2010), 530-543. DOI  |  Pubmed
[19]
D. Wodarz and N. Komarova, Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection, PloS ONE 4 (2009), e4271. DOI
[20]
L. M. Wein, J. T. Wu and D. H. Kirn, Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery, Cancer Res. 63 (2003), 1317-1324. Pubmed
[21]
J. P. Tian, Y. Kuang and H. Yang, Intracellular viral life-cycle induced rich dynamics in tumor virotherapy, Semantic Scholar, 2012, ID: 15696950. Article
[22]
B. S. Choudhury and B. Nasipuri, Efficient virotherapy of cancer in the presence of immune response, Int. J. Dynam. Control 2 (2014), 314-325. DOI
[23]
J. T. Wu, H. M. Byrne, D. H. Kirn and L. M. Wein, Modeling and analysis of a virus that replicates selectively in tumor cells, Bull. Math. Biol. 63 (2001), 731-768. DOI
[24]
A. Friedman, J. P. Tian, G. Fulci, E. A Chiocca and J. Wang, Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity, Cancer Res. 66 (2006), 2314-2319. DOI
[25]
A. Ashyani, O. Rabieimotlagh and H. M. Mohammadinejad, A mathematical approach to effects of CTLs on cancer virotherapy in the second injection of virus, J. Theor. Biol. 453 (2018), 78-87. DOI
[26]
Y. Guo, B. Niu and J. P. Tian, Backward Hopf bifurcation in a mathematical model for oncolytic virotherapy with the infection delay and innate immune effects, J. Biol. Dyn. 13 (2019), 733-748. MR4037114  |  DOI
[27]
S. Khajanchi and J. J. Nieto, Mathematical modeling of tumor-immune competitive system, considering the role of time delay, Appl. Math. Comput. 340 (2019), 180-205. MR3855177
[28]
H. M. Byrne, The effect of time delays on the dynamics of avascular tumor growth, Math. Biosci. 144 (1997), 83-117. MR1478080
[29]
M. Villasana and A. Radunskaya, A delay differential equation model for tumor growth, J. Math. Biol. 47 (2003), 270-294. MR2024382
[30]
D. Ghosh, S. Khajanchi, S. Mangiarotti, F. Denis, S. K. Dana and C. Letellier, How tumor growth can be influenced by delayed interactions between cancer cells and the microenvironment?, BioSystems 158 (2017), 17-30. DOI
[31]
N. Burić and D. Todorović, Dynamics of delay-differential equations modelling immunology of tumor growth, Chaos Solitons Fractals 13 (2002), 645-655. DOI
[32]
P. Bi, S. Ruan and X. Zhang, Periodic and chaotic oscillations in a tumor and immune system interaction model with three delays, Chaos 24 (2014), 023101, 16 pp. MR3403299
[33]
M. Galach, Dynamics of the tumor-immune system competition-the effect of time delay, Int. J. Appl. Math. Comput. Sci. 13 (2003), 395-406. MR2022307  |  Article
[34]
A. d’Onofrio, F. Gatti, P. Cerrai and L. Freschi, Delay-induced oscillatory dynamics of tumour-immune system interaction, Math. Comput. Modelling 51 (2010), 572-591. MR2594708
[35]
D. Wodarz, Viruses as antitumor weapons: defining conditions for tumor remission, Cancer Res. 61 (2001), 3501-3507. Pubmed
[36]
D. Wodarz, Computational approaches to study oncolytic virus therapy: insights and challenges, Gene Ther. Mol. Biol. 8 (2004), 137-146. Article
[37]
R. A. Lamb and G. D. Parks, Paramyxoviridae: the viruses and their replication, in ''Fields Virology'', Vol. 1, B. N. Fields, D. M. Knipe and P. M. Howley, eds., Wolters Kluwer Health-Lippincott Williams and Wilkins, Philadelphia, PA, 2007, 1449-1496. Article
[38]
M. Madigan and J. Martinko, eds., Brock Biology of Microorganisms, 11th ed., Prentice Hall, Upper Saddle River, 2006.
[39]
P. Plattet, L. Alves, M. Herren and H. C. Aguilar, Measles virus fusion protein: Structure, function and inhibition, Viruses 8 (2016), 112. Pubmed  |  DOI
[40]
A. E. Smith and A. Helenius, How viruses enter animal cells, Science 304 (2004), 237-242. Pubmed  |  DOI
[41]
M. Oyama, T. Ohigashi, M. Hoshi, M. Murai, K. Uyemura and T. Yazaki, Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus \(1\) vector \(G207\), Jpn. J. Cancer Res. 91 (2000), 1339-1344. Pubmed  |  DOI
[42]
S. Ruan and J. Wei, On the zeros of third degree exponential polynomial with applications to a delayed model for the control of testosterone secretion, IMA J. Math. Appl. Med. Biol. 18 (2001), 41-52. Pubmed
[43]
A. S. Novozhilov, F. S. Berezovskaya, E. V. Koonin and G. P. Karev, Mathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models, Biol. Direct. 1 (2006), 1-6. Pubmed  |  DOI
[44]
A. d'Onofrio, Metamodeling tumour-immune system interaction, tumour evasion and immunotherapy, Math. Comput. Modelling 47 (2008), 614-637. MR2396795
[45]
B. A. Fuchs and V. I. Levin, Functions of a complex variable and some of their applications, Vol. II, Pergamon Press, London, 1961. MR0132818

Home Riv.Mat.Univ.Parma